Triple combination therapies for anti-aging
US-2024316086-A1 · Sep 26, 2024 · US
Doxycycline composition
US9561242B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9561242-B2 |
| Application number | US-201615013122-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 2, 2016 |
| Priority date | Jul 9, 2014 |
| Publication date | Feb 7, 2017 |
| Grant date | Feb 7, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.
First claim
Opening claim text (preview).
We claim: 1. A once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition contains up to 40 mg of doxycycline. 2. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition contains from 24 mg to 40 mg of doxycycline. 3. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition contains 40 mg of doxycycline. 4. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition contains 36 mg of doxycycline. 5. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition contains 32 mg of doxycycline. 6. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition contains 30 mg of doxycycline. 7. The once daily pharmaceutical composition according to claim 1 , wherein the doxycycline is present as a salt, hydrate, or a solvate. 8. The once daily pharmaceutical composition according to claim 7 , wherein the doxycycline is present as doxycycline hyclate. 9. The once daily pharmaceutical composition according to claim 7 , wherein the doxycycline is present as doxycycline monohydrate. 10. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is a capsule or a tablet. 11. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is in the form of pellets, beads, beadlets, granules, spheres or spheroids, minitablets, particles, or powders. 12. The once daily pharmaceutical composition according to claim 10 , wherein the pharmaceutical composition is a capsule filled with one or more of pellets, beads, beadlets, granules, spheres or spheroids, minitablets, particles, or powders. 13. The once daily pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition exhibits a reduced food effect such that the food effect on C max is less than 40% and/or AUC 0-t is less than 20% as compared to when the pharmaceutical composition is administered in a fasted state. 14. A method of treating rosacea by administering to a person in need thereof a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition contains up to 40 mg of doxycycline.
Assignees
Inventors
Classifications
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates · CPC title
containing drug in at least two layers or in the core and in at least one outer layer · CPC title
Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose · CPC title
- A61K31/65Primary
Tetracyclines · CPC title
with microcapsules or coated microparticles according to A61K9/50 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9561242B2 cover?
- The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.
- Who is the assignee on this patent?
- Sun Pharmaceutical Ind Ltd
- What technology area does this patent fall under?
- Primary CPC classification A61K31/65. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).